Showing 4461-4470 of 5556 results for "".
- Breaking News From Fall Clinical: Lebrikizumab Performs Well for Up to Two Years in ADhttps://practicaldermatology.com/news/ears-experienced-sustained-skin-clearance-itch-relief-and-reduced-disease-severity-with-monthly-maintenance-dosing-as-demonstrated-in-the-adjo/2462083/Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing, according to data from the ADjoin long-term extensi
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated c
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Lebrikizumab Update: IL-13 Blocker Performs Well in AD Inadequately Controlled With Cyclosporinehttps://practicaldermatology.com/news/lebrikizumab-update-il-13-blocker-performs-well-in-ad-inadequately-controlled-with-cyclosporine/2462070/Lebrikizumab showed clinical improvements in combination with topical corticosteroids (TCS) in adult and adolescent patients with moderate-to-severe atopic dermatitis (AD) that was not adequately controlled with cyclosporine or for whom cyclosporine was not medically adv
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma
- InMode: Employees in Isreal Are Safehttps://practicaldermatology.com/news/inmode-employees-in-isreal-are-safe/2462053/InMode Ltd. has affirmed the safety of the employees at the Company's Yokneam, Israel headquarters and does not anticipate any interruption in productionas a result of the Israel-Hamas War, "InMode is committed to supporting all customers, distributors, employees, and
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R),
- FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-cream-03-for-treatment-of-psoriasis-in-children-ages-6-to-11/2462045/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) to expand the indication of ZORYVE (roflumilast) cream 0.3% for the topical treatment of plaque psoriasis, including intertriginous areas, to children ages 6 to 11 years. “T
- Revealed: Key Genes That May Up Nodular Melanoma Riskhttps://practicaldermatology.com/news/revealed-key-genes-that-may-up-nodular-melanoma-risk/2462038/New research sheds light on gene variants which may contribute to higher risk for nodular melanoma. Nodular melanoma accounts for around 14% of invasive melanoma cases, but the aggressive subtype is the largest contributor to melanoma deaths. “Nodular melanoma is often detect
- NEA Launches #OneThingAboutEczema Campaign for Eczema Awareness Monthhttps://practicaldermatology.com/news/nea-launches-onethingabouteczema-campaign-for-eczema-awareness-month/2462029/The National Eczema Association (NEA) is highlighting different aspects of living with eczema for its annua